Join Agomab Therapeutics for a virtual management and key opinion leader (KOL) event on the positive topline data from the STENOVA open-label extension (OLE) study of ontunisertib in Fibrostenosing Crohn’s Disease (FSCD).

The event will feature Florian Rieder, MD, who will join company executives Tim Knotnerus (CEO), Philippe Wiesel (CMO), and Pierre Kemula (CFO) to discuss the progress with ontunisertib, the Company’s investigational, oral, gastrointestinal-restricted small molecule inhibitor of ALK5 (TGFβR1) in clinical development for FSCD as well as next steps for the program. A live question and answer session will follow the formal presentation.